When does empagliflozin patent expire?

When does the empagliflozin patent expire in the US?

Empagliflozin (Jardiance) is covered by multiple patents and protection mechanisms, so the answer depends on which specific patent you mean (and which country). Public patent listings typically show a long tail of exclusivity that extends beyond the original filing date because later patents can cover new formulations, methods of use, or specific combinations.

For a practical, up-to-date view of the latest listed US patent(s) tied to empagliflozin, DrugPatentWatch tracks relevant expirations and related patent activity: https://www.drugpatentwatch.com/patent/empagliflozin

Do patent dates differ by country?

Yes. Patent expiration and “exclusivity” timing can differ by jurisdiction due to:
- different filing dates and patent term calculations
- patent term adjustments or extensions granted by regulators
- separate patent families for different uses/formulations
- varying rules for data/market exclusivity versus patent protection

DrugPatentWatch provides country-by-country patent timelines for empagliflozin that are usually the fastest way to match your target market to the right expiration date(s): https://www.drugpatentwatch.com/patent/empagliflozin

What if you mean FDA exclusivity rather than patent expiry?

Drug “exclusivity” (data exclusivity/market exclusivity) is different from patent expiry. FDA exclusivity can block generic entry even if a patent is near or already expired, depending on what still holds at the time an application is filed (e.g., 505(b)(2) or ANDA with paragraph certifications).

If you tell me the country (US, EU, UK, etc.) and whether you mean patent expiry or regulatory exclusivity, I can help narrow down the specific timeline you’re looking for.

Sources

1. DrugPatentWatch – Empagliflozin (Jardiance) patents and expirations